Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 13:00 ET | Source: DelveInsight Business Research LLP

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

New York, USA, April 14, 2026 (GLOBE NEWSWIRE) -- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight The psoriasis clinical trial...
April 14, 2026 12:30 ET | Source: Sanofi Winthrop Industrie

Sanofi: Informations relatives au nombre de droits de vote et d'actions - MARS 2026

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
April 14, 2026 12:30 ET | Source: Sanofi Winthrop Industrie

Sanofi: Information concerning the total number of voting rights and shares - March 2026

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
April 14, 2026 11:03 ET | Source: Research and Markets

Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Research and Global Forecast Report 2026-2035

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026" has been added to ...
April 13, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such...
April 13, 2026 11:37 ET | Source: American Kidney Fund

American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership...
April 13, 2026 09:21 ET | Source: Research and Markets

Smart Packaging and Electronic Patient Information Training Course: Overview of the Current Technologies, Patient and Societal Benefits and Building Blocks (ONLINE EVENT: May 21, 2026)

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Smart Packaging and Electronic Patient Information (May 21, 2026)" training has been added to ResearchAndMarkets.com's offering.This course will...
April 13, 2026 06:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody...
April 13, 2026 05:14 ET | Source: Research and Markets

Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights...
April 13, 2026 01:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...